No abstract

Short-term intravenous dosing of liposomal curcumin appears to be safe up to a dose of 120 mg/m2. Changes in red blood cell morphology may represent a dose limiting sign of toxicity.

No abstract

492S troke is a major healthcare problem attributable to ≈10% of deaths worldwide. 1 In industrialized countries, stroke is the third most common cause of death, and the leading cause of disability, with 20% of survivors requiring institutional care after 3 months and 15% to 30% being permanently disabled. 2Because of the aging population, the risk of stroke is predicted to rise even further.3 As most strokes and transient ischemic attacks (TIAs) are caused by a thromboembolic occlusion of cerebral arteries, antithrombotic agents are the cornerstone of stroke prevention.The benefit of antiplatelet agents is uncertain in primary prevention. 4 In contrast, antiplatelet agents such as aspirin, clopidogrel, or the combination of aspirin and extended-release dipyridamole are recommended for secondary prevention in patients who have experienced a noncardioembolic stroke or transient ischemic attack (TIA).5-7 The probability of a recurrent stroke after the first stroke is >3% to 10% in the first month and ≈5% to 14% in the first year. 8,9 A recurrent stroke event can be devastating, with twice the probability of death and increased cardiovascular complications as compared with the first stroke.10 A necessary balance between risks (bleeding complications) and benefits (reduction in ischemic events) makes the search for ADP receptor inhibitors challenging.Aspirin, the most widely used antiplatelet agent, reduces the relative risk of recurrent vascular events by 13% to 22% and the risk of recurrent stroke by 15% as compared with placebo. 4,6 Clopidogrel monotherapy has been shown to be superior to aspirin when measured by a composite end point of stroke, myocardial infarction, or vascular death in the CAPRIE (Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Background and Purpose-The efficacy and safety of different antiplatelet regimes for prevention of stroke in patients at high risk were investigated in a systematic review and meta-analysis. Methods-We

No abstract